Verici Dx (LSE:VRCI) Buildings And Improvements : £0.00 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Verici Dx Buildings And Improvements?

Verici Dx's quarterly buildings and improvements increased from Jun. 2023 (£0.00 Mil) to Dec. 2023 (£1.02 Mil) but then declined from Dec. 2023 (£1.02 Mil) to Jun. 2024 (£0.00 Mil).

Verici Dx's annual buildings and improvements increased from Dec. 2021 (£0.00 Mil) to Dec. 2022 (£1.06 Mil) but then declined from Dec. 2022 (£1.06 Mil) to Dec. 2023 (£1.02 Mil).

Verici Dx Buildings And Improvements Historical Data

The historical data trend for Verici Dx's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Buildings And Improvements Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

1.06

1.02

Verici Dx Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Buildings And Improvements	Get a 7-Day Free Trial			-	1.06	-	1.02	-

Verici Dx Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

63V:Germany

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines